Position in NVS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$0
New position
Shares Held
0
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2026
1 quarter on record
Derivatives in NVS
reported options exposure · as of Jun 30, 2026CallValue
$7,836,000
CallShares
50,000
PutValue
$15,672,000
PutShares
100,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026DIADEMA PARTNERS LP holds $10,595,985 across 3 Drug Manufacturers - General names.
All Filings in NVS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $15,672,000 | 100,000 | Put | Sole | 2026-08-14 | |
| 2026-06-30 | $7,836,000 | 50,000 | Call | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||